DK0965343T3 - Ziprasidonformuleringer - Google Patents

Ziprasidonformuleringer

Info

Publication number: DK0965343T3
Authority: DK; Denmark
Prior art keywords: ziprasidone; formulations; ziprasidone formulations
Prior art date: 1998-06-15

Application number

DK99304451T

Other languages

English (en)

Inventor

Frank Robert Busch

Angela Carol Gatlin Hausberger

Bijan Rasadi

Daniel Ray Arenson

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-15

Filing date

1999-06-08

Publication date

2003-08-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22216447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0965343(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-06-08 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2003-08-04 Application granted granted Critical

2003-08-04 Publication of DK0965343T3 publication Critical patent/DK0965343T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Organic Chemistry (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Detergent Compositions (AREA)
Feeding Of Articles By Means Other Than Belts Or Rollers (AREA)
Polyamides (AREA)

DK99304451T 1998-06-15 1999-06-08 Ziprasidonformuleringer DK0965343T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US8922998P	1998-06-15	1998-06-15

Publications (1)

Publication Number	Publication Date
DK0965343T3 true DK0965343T3 (da)	2003-08-04

Family

ID=22216447

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK99304451T DK0965343T3 (da)	1998-06-15	1999-06-08	Ziprasidonformuleringer

Country Status (45)

Country	Link
US (1)	US6150366A (da)
EP (1)	EP0965343B1 (da)
JP (2)	JP3441676B2 (da)
KR (1)	KR100338915B1 (da)
CN (1)	CN1307994C (da)
AP (1)	AP1216A (da)
AR (1)	AR015553A1 (da)
AT (1)	ATE240732T1 (da)
AU (1)	AU753820B2 (da)
BG (1)	BG64691B1 (da)
BR (1)	BR9902268A (da)
CA (1)	CA2274338C (da)
CO (1)	CO5070579A1 (da)
CY (1)	CY2003002I1 (da)
CZ (1)	CZ297954B6 (da)
DE (1)	DE69908021T2 (da)
DK (1)	DK0965343T3 (da)
EA (1)	EA002223B1 (da)
ES (1)	ES2197581T3 (da)
GT (1)	GT199900080A (da)
HK (1)	HK1024184A1 (da)
HN (1)	HN1999000089A (da)
HR (1)	HRP990193B1 (da)
HU (1)	HU226487B1 (da)
ID (1)	ID23546A (da)
IL (1)	IL130424A (da)
IS (1)	IS2182B (da)
MA (1)	MA26647A1 (da)
MY (1)	MY121397A (da)
NO (1)	NO316713B1 (da)
NZ (1)	NZ336271A (da)
OA (1)	OA11064A (da)
PA (1)	PA8475601A1 (da)
PE (1)	PE20000632A1 (da)
PL (2)	PL195209B1 (da)
PT (1)	PT965343E (da)
RS (1)	RS49611B (da)
SG (1)	SG77243A1 (da)
SI (1)	SI0965343T1 (da)
SK (1)	SK286245B6 (da)
TR (1)	TR199901379A2 (da)
TW (1)	TW590774B (da)
UA (1)	UA59383C2 (da)
UY (1)	UY25649A1 (da)
ZA (1)	ZA993938B (da)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20080113025A1 (en) *	1998-11-02	2008-05-15	Elan Pharma International Limited	Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US7175855B1 (en)	1999-05-27	2007-02-13	Pfizer Inc.	Ziprasidone suspension
DE60001649T2 (de) *	1999-05-27	2003-08-21	Pfizer Prod Inc	Ziprasidonsuspension
CA2389235C (en)	1999-10-29	2007-07-17	Euro-Celtique, S.A.	Controlled release hydrocodone formulations
US10179130B2 (en)	1999-10-29	2019-01-15	Purdue Pharma L.P.	Controlled release hydrocodone formulations
CN101653411A (zh)	2000-10-30	2010-02-24	欧罗赛铁克股份有限公司	控释氢可酮制剂
UY27668A1 (es) *	2002-02-20	2003-10-31	Pfizer Prod Inc	Composición de ziprasidona y controles sintéticos
US20040048876A1 (en) *	2002-02-20	2004-03-11	Pfizer Inc.	Ziprasidone composition and synthetic controls
WO2003097046A1 (en) *	2002-05-17	2003-11-27	Duke University	Method for treating obesity
US7488729B2 (en) *	2002-12-04	2009-02-10	Dr. Reddy's Laboratories Limited	Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof
WO2004050655A1 (en) *	2002-12-04	2004-06-17	Dr. Reddy's Laboratories Limited	Polymorphic forms of ziprasidone and its hydrochloride
US20050143396A1 (en) *	2003-04-11	2005-06-30	Hertero Drugs Limited	Novel crystalline forms of ziprasidone hydrochloride
EP2316456B1 (en)	2003-04-29	2017-06-14	Orexigen Therapeutics, Inc.	Compositions for affecting weight loss comprising an opioid antagonist and bupropion
KR20060015750A (ko) *	2003-06-03	2006-02-20	테바 파마슈티컬 인더스트리즈 리미티드	지프라시돈 ＨＣｌ의 다형 형태 및 그 제조 방법
US20050049295A1 (en) *	2003-06-12	2005-03-03	Dr. Reddy's Laboratories Limited	Process for the preparation of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1piperazinyl) ethyl)-6-chloro-1, 3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride) and its intermediate
RU2351316C2 (ru) *	2003-09-02	2009-04-10	Пфайзер Продактс Инк.	Лекарственные формы с замедленным высвобождением зипразидона
US7667037B2 (en) *	2003-10-24	2010-02-23	Teva Pharmaceutical Industries Ltd.	Processes for preparation of ziprasidone
AU2003285600A1 (en) *	2003-11-28	2005-06-24	Siddiqui Mohammed Jaweed Mukarram	Process for the preparing ziprasidone monohydrochloride hydrate
WO2005061493A2 (en)	2003-12-18	2005-07-07	Teva Pharmaceutical Industries Ltd.	Polymorphic form b2 of ziprasidone base
WO2005065660A2 (en) *	2003-12-31	2005-07-21	Alpharma, Inc.	Ziprasidone formulations
BRPI0506829A (pt) *	2004-01-13	2007-05-29	Univ Duke	composições de anticonvulsivo e droga antipsicótica e métodos para sua utilização para afetar perda de peso
US7713959B2 (en) *	2004-01-13	2010-05-11	Duke University	Compositions of an anticonvulsant and mirtazapine to prevent weight gain
DE602005018171D1 (de) *	2004-02-27	2010-01-21	Ranbaxy Lab Ltd	Verfahren zur herstellung von ziprasidon
CA2565154A1 (en) *	2004-05-03	2005-11-24	Duke University	Compositions for affecting weight loss
WO2005107719A2 (en) *	2004-05-06	2005-11-17	Sandoz Ag	Pharmaceutical composition comprising hydrophobic drug having improved solubility
CA2467538C (en) *	2004-05-14	2010-08-24	Apotex Pharmachem Inc.	New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
WO2005123086A2 (en) *	2004-06-11	2005-12-29	Dr. Reddy's Laboratories Ltd.	Ziprasidone dosage form
CA2471219A1 (en) *	2004-06-14	2005-12-14	Apotex Pharmachem Inc.	Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
US9044503B2 (en) *	2004-08-27	2015-06-02	University Of Kentucky Research Foundation	Amyloid peptide inactivating enzyme to treat alzheimer's disease peripherally
US20090142404A1 (en) *	2004-08-31	2009-06-04	Pfizer Inc	Pharmaceutical dosage forms comprising a low-solubility drug and a polymer
JP5324098B2 (ja) *	2004-11-16	2013-10-23	アルケルメスファーマアイルランドリミテッド	注射可能なナノ粒子のオランザピン製剤
US20080268034A1 (en) *	2005-01-07	2008-10-30	Girish Karanth	Solid Oral Dosage Forms of Ziprasidone Containing Colloidal Silicone Dioxide
US7749529B2 (en) *	2005-02-08	2010-07-06	Ash Access Technology, Inc.	Catheter lock solution comprising citrate and a paraben
WO2006086779A1 (en) *	2005-02-11	2006-08-17	Teva Pharmaceutical Industries Ltd.	Amorphous ziprasidone mesylate
ITMI20050346A1 (it)	2005-03-07	2006-09-08	Dipharma Spa	Forma solida di ziprasidone cloridrato
CA2500667C (en) *	2005-03-11	2013-01-15	Apotex Pharmachem Inc.	Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions
CA2599391A1 (en) *	2005-03-14	2006-09-21	Teva Pharmaceutical Industries Ltd.	Crystalline forms of ziprasidone mesylate
WO2006099452A1 (en) *	2005-03-14	2006-09-21	Teva Pharmaceutical Industries Ltd.	Anhydrous ziprasidone mesylate and a process for its preparation
NZ561950A (en) *	2005-04-13	2010-09-30	Pfizer Prod Inc	Injectable depot formulations comprising ziprasidone in nanoparticle form with two surface stabilizers
US20080305161A1 (en) *	2005-04-13	2008-12-11	Pfizer Inc	Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
CA2605447A1 (en) *	2005-04-22	2006-11-02	Wyeth	Therapeutic combinations for the treatment or prevention of psychotic disorders
KR101380088B1 (ko)	2005-05-26	2014-04-10	다이닛본 스미토모 세이야꾸 가부시끼가이샤	약학 조성물
CN101242813A (zh) *	2005-06-20	2008-08-13	依兰药物国际有限公司	包含芳基-杂环化合物的毫微粒和控制释放组合物
CA2613474A1 (en) *	2005-06-20	2007-03-08	Elan Pharma International Limited	Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds
JP5180092B2 (ja)	2005-11-22	2013-04-10	オレキシジェン・セラピューティクス・インコーポレーテッド	インスリン感受性を増すための組成物および方法
DK1954241T3 (da) *	2005-11-28	2012-06-18	Orexigen Therapeutics Inc	Zonisamid-formulering med vedvarende frigivelse
PL379569A1 (pl) *	2006-04-28	2007-10-29	Pliva Kraków Zakłady Farmaceutyczne Spółka Akcyjna	Sposób wytwarzania kompozycji farmaceutycznej zawierającej substancję aktywną ziprasidone lub jego farmaceutycznie dopuszczalną sól zwiększający rozpuszczalność i biodostępność tego leku, kompozycja farmaceutyczna i zastosowanie hydrofilowych substancji pomocniczych
US8916195B2 (en)	2006-06-05	2014-12-23	Orexigen Therapeutics, Inc.	Sustained release formulation of naltrexone
EP1892243A1 (en) *	2006-08-02	2008-02-27	KRKA, tovarna zdravil, d.d., Novo mesto	Polymorphic forms of ziprasidone sulphate salts
EP1889844A3 (en) *	2006-08-02	2008-03-05	Krka	Polymorphic forms of ziprasidone sulphates
KR101654176B1 (ko)	2006-11-09	2016-09-09	오렉시젠 세러퓨틱스 인크.	신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
AU2007319472B2 (en)	2006-11-09	2013-01-17	Nalpropion Pharmaceuticals Llc	Methods Of Administering Weight Loss Medications
US20080286373A1 (en) *	2007-05-18	2008-11-20	Palepu Nageswara R	Ziprasidone formulations
EP2197446A4 (en) *	2007-08-31	2012-01-25	Reddys Lab Ltd Dr	PREPARATION OF HYDROCHLORIDE OF ZIPRASIDONE MONOHYDRATE
US8410268B2 (en) *	2008-03-11	2013-04-02	Alkem Laboratories Limited	Process for the preparation of ziprasidone
US20110144145A1 (en)	2008-05-30	2011-06-16	Orexigen Therapeutics, Inc.	Methods for treating visceral fat conditions
DE102008045854A1 (de)	2008-09-05	2010-03-11	Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg	Partikel aus Ziprasidone und einem Sprengmittel enthaltende Pharmazeutische Zusammensetzung
CA2937222C (en) *	2009-06-25	2019-06-04	Alkermes Pharma Ireland Limited	Prodrugs of nh-acidic compounds
EP2340834A1 (en)	2009-12-30	2011-07-06	Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi	Enhanced Solubility of Ziprasidone
KR101841442B1 (ko)	2010-01-11	2018-03-23	오렉시젠 세러퓨틱스 인크.	주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
SI3257500T1 (sl)	2010-02-25	2019-12-31	Bristol-Myers Squibb Holdings Ireland Unlimited Company	Formulacije apiksabana
WO2011148253A2 (en)	2010-05-25	2011-12-01	Aurobindo Pharma Limited	Solid dosage forms of antipsychotics
SI23610A (sl)	2011-01-13	2012-07-31	Diagen@d@o@o	Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
RS63569B1 (sr)	2012-06-06	2022-10-31	Nalpropion Pharmaceuticals Llc	Ompozicija za upotrebu u metodi lečenja prekomerne težine i gojaznosti kod pacijenata sa visokim kardiovaskularnim rizikom
CA2891122C (en)	2012-11-14	2021-07-20	The Johns Hopkins University	Methods and compositions for treating schizophrenia
CA3092335A1 (en)	2018-03-05	2019-09-12	Alkermes Pharma Ireland Limited	Aripiprazole dosing strategy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5264446A (en) *	1980-09-09	1993-11-23	Bayer Aktiengesellschaft	Solid medicament formulations containing nifedipine, and processes for their preparation
MX173362B (es) *	1987-03-02	1994-02-23	Pfizer	Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4831031A (en) *	1988-01-22	1989-05-16	Pfizer Inc.	Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US4883795A (en) *	1988-01-22	1989-11-28	Pfizer Inc.	Piperazinyl-heterocyclic compounds
DE4141268A1 (de) *	1991-12-14	1993-06-17	Merck Patent Gmbh	Pharmazeutische zubereitung
US5338846A (en) *	1992-08-26	1994-08-16	Pfizer Inc.	Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt
US5206366A (en) *	1992-08-26	1993-04-27	Pfizer Inc.	Process for preparing aryl piperazinyl-heterocyclic compounds
US5312925A (en) *	1992-09-01	1994-05-17	Pfizer Inc.	Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5359068A (en) *	1993-06-28	1994-10-25	Pfizer Inc.	Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
EP0790236B1 (en) *	1996-02-13	2003-11-19	Pfizer Inc.	Pro-drugs of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
ATE364374T1 (de) *	1997-08-11	2007-07-15	Pfizer Prod Inc	Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit

1999
- 1999-05-27 US US09/320,985 patent/US6150366A/en not_active Expired - Lifetime
- 1999-06-04 HN HN1999000089A patent/HN1999000089A/es unknown
- 1999-06-08 AT AT99304451T patent/ATE240732T1/de active
- 1999-06-08 PT PT99304451T patent/PT965343E/pt unknown
- 1999-06-08 DK DK99304451T patent/DK0965343T3/da active
- 1999-06-08 ES ES99304451T patent/ES2197581T3/es not_active Expired - Lifetime
- 1999-06-08 SI SI9930316T patent/SI0965343T1/xx unknown
- 1999-06-08 EP EP99304451A patent/EP0965343B1/en not_active Expired - Lifetime
- 1999-06-08 DE DE69908021T patent/DE69908021T2/de not_active Expired - Lifetime
- 1999-06-08 GT GT199900080A patent/GT199900080A/es unknown
- 1999-06-09 TW TW088109645A patent/TW590774B/zh not_active IP Right Cessation
- 1999-06-09 AU AU33983/99A patent/AU753820B2/en not_active Ceased
- 1999-06-09 SK SK769-99A patent/SK286245B6/sk not_active IP Right Cessation
- 1999-06-10 SG SG1999002794A patent/SG77243A1/en unknown
- 1999-06-10 AP APAP/P/1999/001579A patent/AP1216A/en active
- 1999-06-10 IL IL13042496A patent/IL130424A/xx not_active IP Right Cessation
- 1999-06-11 MY MYPI99002412A patent/MY121397A/en unknown
- 1999-06-11 TR TR1999/01379A patent/TR199901379A2/xx unknown
- 1999-06-11 PE PE1999000523A patent/PE20000632A1/es not_active Application Discontinuation
- 1999-06-11 IS IS5079A patent/IS2182B/is unknown
- 1999-06-11 CA CA002274338A patent/CA2274338C/en not_active Expired - Lifetime
- 1999-06-11 AR ARP990102822A patent/AR015553A1/es active IP Right Grant
- 1999-06-14 ZA ZA9903938A patent/ZA993938B/xx unknown
- 1999-06-14 HR HR990193A patent/HRP990193B1/xx not_active IP Right Cessation
- 1999-06-14 RS YUP-271/99A patent/RS49611B/sr unknown
- 1999-06-14 PL PL333737A patent/PL195209B1/pl not_active IP Right Cessation
- 1999-06-14 PA PA19998475601A patent/PA8475601A1/es unknown
- 1999-06-14 OA OA9900126A patent/OA11064A/en unknown
- 1999-06-14 KR KR1019990021977A patent/KR100338915B1/ko not_active IP Right Cessation
- 1999-06-14 NO NO19992892A patent/NO316713B1/no not_active IP Right Cessation
- 1999-06-14 HU HU9901960A patent/HU226487B1/hu not_active IP Right Cessation
- 1999-06-14 CN CNB991111192A patent/CN1307994C/zh not_active Expired - Fee Related
- 1999-06-14 JP JP16677399A patent/JP3441676B2/ja not_active Expired - Lifetime
- 1999-06-14 PL PL380276A patent/PL195606B1/pl not_active IP Right Cessation
- 1999-06-14 UA UA99063279A patent/UA59383C2/uk unknown
- 1999-06-14 CZ CZ0212799A patent/CZ297954B6/cs not_active IP Right Cessation
- 1999-06-14 NZ NZ336271A patent/NZ336271A/xx not_active IP Right Cessation
- 1999-06-14 ID IDP990571D patent/ID23546A/id unknown
- 1999-06-14 MA MA25621A patent/MA26647A1/fr unknown
- 1999-06-14 BG BG103489A patent/BG64691B1/bg unknown
- 1999-06-15 EA EA199900467A patent/EA002223B1/ru not_active IP Right Cessation
- 1999-06-15 CO CO99037319A patent/CO5070579A1/es unknown
- 1999-06-15 BR BR9902268-0A patent/BR9902268A/pt not_active Application Discontinuation
- 1999-08-10 UY UY25649A patent/UY25649A1/es unknown
2000
- 2000-06-16 HK HK00103630A patent/HK1024184A1/xx not_active IP Right Cessation
2001
- 2001-06-11 JP JP2001175276A patent/JP4187423B2/ja not_active Expired - Lifetime
2003
- 2003-11-20 CY CY200300002C patent/CY2003002I1/el unknown

Also Published As

Publication number	Publication date
IL130424A0 (en)	2000-06-01
PL195209B1 (pl)	2007-08-31
EA199900467A2 (ru)	1999-12-29
ID23546A (id)	2000-05-04
ES2197581T3 (es)	2004-01-01
JP3441676B2 (ja)	2003-09-02
CO5070579A1 (es)	2001-08-28
PA8475601A1 (es)	2000-09-29
KR100338915B1 (ko)	2002-05-30
AP1216A (en)	2003-10-19
TW590774B (en)	2004-06-11
HU226487B1 (en)	2009-03-02
IS2182B (is)	2006-12-15
GT199900080A (es)	2000-11-29
AR015553A1 (es)	2001-05-02
HU9901960D0 (en)	1999-08-30
NO992892D0 (no)	1999-06-14
EA199900467A3 (ru)	2000-04-24
SI0965343T1 (en)	2003-10-31
PL333737A1 (en)	1999-12-20
OA11064A (en)	2002-03-13
EP0965343A3 (en)	2000-02-23
SK286245B6 (sk)	2008-06-06
CA2274338C (en)	2003-04-15
DE69908021D1 (de)	2003-06-26
RS49611B (sr)	2007-06-04
SK76999A3 (en)	2000-12-11
AU3398399A (en)	1999-12-23
SG77243A1 (en)	2000-12-19
YU27199A (sh)	2002-12-10
UY25649A1 (es)	2000-02-23
HRP990193A2 (en)	2000-02-29
CY2003002I1 (el)	2009-11-04
PT965343E (pt)	2003-08-29
BG103489A (en)	2000-07-31
EP0965343A2 (en)	1999-12-22
PL195606B1 (pl)	2007-10-31
HUP9901960A2 (hu)	2000-08-28
CA2274338A1 (en)	1999-12-15
JP4187423B2 (ja)	2008-11-26
PE20000632A1 (es)	2000-07-26
EA002223B1 (ru)	2002-02-28
CZ297954B6 (cs)	2007-05-09
ZA993938B (en)	2000-12-14
JP2000007566A (ja)	2000-01-11
MY121397A (en)	2006-01-28
HN1999000089A (es)	1999-11-03
CZ212799A3 (cs)	2000-09-13
JP2002003492A (ja)	2002-01-09
ATE240732T1 (de)	2003-06-15
NO992892L (no)	1999-12-16
CN1307994C (zh)	2007-04-04
IS5079A (is)	1999-12-16
IL130424A (en)	2003-10-31
CN1242987A (zh)	2000-02-02
NZ336271A (en)	2000-10-27
EP0965343B1 (en)	2003-05-21
BR9902268A (pt)	2000-05-02
BG64691B1 (bg)	2005-12-30
HK1024184A1 (en)	2000-10-05
NO316713B1 (no)	2004-04-13
HUP9901960A3 (en)	2000-09-28
UA59383C2 (uk)	2003-09-15
DE69908021T2 (de)	2003-11-27
US6150366A (en)	2000-11-21
KR20000006143A (ko)	2000-01-25
TR199901379A2 (xx)	2000-01-21
HRP990193B1 (en)	2003-08-31
AU753820B2 (en)	2002-10-31
AP9901579A0 (en)	1999-06-30
MA26647A1 (fr)	2004-12-20

Publication	Publication Date	Title
DK0965343T3 (da)	2003-08-04	Ziprasidonformuleringer
IS5555A (is)	2000-06-30	Selekoxib lyfjablöndur
ID30031A (id)	2001-11-01	Formulasi-formulasi agrokimia
NO20004240L (no)	2000-10-18	Formuleringer
ATE224703T1 (de)	2002-10-15	Brauseformulierungen
PT1130966E (pt)	2005-04-29	Formulacoes antiparasitarias
PT1096937E (pt)	2005-04-29	Formulacoes de ranolazina de libertacao prolongada
DE69805443D1 (de)	2002-06-20	Sachet-formulierungen
MA24473A1 (fr)	1998-10-01	Formulations
ID29635A (id)	2001-09-06	Formulasi mikrokapsul
CY2006006I1 (el)	2009-11-04	Πρωτεϊνικα σκευασματα
ID23458A (id)	2000-04-27	Bentuk sediaan nefazodon
DE69920073D1 (de)	2004-10-21	kinderschutzhöschen
IS6398A (is)	2002-05-27	Lyfjablöndur
DE69935609D1 (de)	2007-05-03	Formulierungen enthaltend cefuroxim-axetil
ID27655A (id)	2001-04-19	Formulasi mikrokapsul
EP1192168A4 (en)	2003-04-16	galectin
ATA208398A (de)	1999-12-15	Handstück
SE9800170D0 (sv)	1998-01-22	Formulation
SE9800766D0 (sv)	1998-03-09	Formulation
ITPS990017U1 (it)	2000-11-20	Leeran 1 (lorean)
FI3880U1 (fi)	1999-04-12	Tarjoilusetti
SE9900910D0 (sv)	1999-03-11	FreezeBox 2000
SE9901602D0 (sv)	1999-05-04	Jet-tröska 2000
FI3554U1 (fi)	1998-08-31	Teline